Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B

Not Applicable

Completed

• Conditions: Influenza A; Influenza B
• Interventions: Device: Respirio Flu Test; Device: Reverse Transcriptase Polymerase Chain Reaction (RT-PCR); Device: Sofia® Influenza A+B Fluorescent Immunoassay (FIA)

• Registration Number: NCT02487173
• Lead Sponsor: Ellume Pty Ltd

Brief Summary

The primary purpose of this study is to validate the sensitivity and specificity of the Respirio Flu Test in detecting Influenza A, when used by subjects, as compared to the gold standard for detection, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).

The secondary aims are to:

* validate the sensitivity and specificity of the Respirio Flu Test in detecting Influenza B , when used by subjects, as compared to the gold standard for detection, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).

* assess agreement (positive and negative) between Respirio Flu Test and Sofia® Influenza A+B Test in detecting Influenza A;

* assess agreement (positive and negative) between Respirio Flu Test and Sofia® Influenza A+B Test in detecting Influenza B;

* evaluate the correct interpretation of the Respirio Flu Test results by subjects with Influenza-like illness symptoms;

* evaluate the subjects' satisfaction with the convenience, comfort and ease of use of the Respirio Flu Test;

* evaluate the subjects' comprehension of the Respirio Flu Test labelling; and

* establish the minimum sample weight required to achieve a result with the Respirio Flu Test.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-06-26
• Study First Submitted QC: 2015-06-30
• Study First Posted: 2015-07-01
• Study Start: 2015-09
• Primary Completion: 2015-12
• Study Completion: 2015-12
• Status Verified: 2016-07
• Last Update Submitted: 2016-07-14
• Last Update Posted: 2016-07-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 83

Inclusion Criteria

• Male and female subjects aged ≥ 1 year;
• Rhinorrhea;
• ≤ 72 hours from onset of Influenza-like illness symptoms;
• Subject (or parent/legal guardian) capable and willing to give informed consent/assent.
• Subject (or parent/legal guardian) able to read and write in English.

Exclusion Criteria

• Has undergone treatment with antivirals within the previous 7 days;
• Has been vaccinated by means of an Influenza nasal spray/mist vaccine within the previous 7 days;
• Recent craniofacial injury or surgery, including surgery to correct deviation of the nasal septum, within the previous 6 months;
• Currently enrolled in another clinical trial or used any investigational device within 90 days preceding informed consent;
• Has had prior exposure to the Respirio Flu Test;
• Subject (or parent/legal guardian) residing at the same residential address as a subject currently enrolled in this study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Respirio Flu Test	Respirio Flu Test	Upper respiratory tract samples from participants will be tested with: * Respirio Flu Test * Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) * Sofia® Influenza A+B Fluorescent Immunoassay (FIA)
Respirio Flu Test	Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)	Upper respiratory tract samples from participants will be tested with: * Respirio Flu Test * Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) * Sofia® Influenza A+B Fluorescent Immunoassay (FIA)
Respirio Flu Test	Sofia® Influenza A+B Fluorescent Immunoassay (FIA)	Upper respiratory tract samples from participants will be tested with: * Respirio Flu Test * Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) * Sofia® Influenza A+B Fluorescent Immunoassay (FIA)

Primary Outcome Measures

Name	Time	Method
Of participants negative for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza A by Respirio Flu Test.	Day 1	Establish specificity against a gold standard. Report as a percentage of participants with 95% confidence limits.
Of participants positive for influenza A by ReverseTranscriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza A by Respirio Flu Test.	Day 1	Establish sensitivity against a gold standard. Report as a percentage of participants with 95% confidence limits.

Secondary Outcome Measures

Name	Time	Method
Percent of participants who correctly interpret result of Respirio Flu Test.	Day 1	Agreement between trained staff and participants. Report as a percentage of participants with 95% confidence limits.
Weight of sample deposited in Respirio Flu Test.	Day 1	Establish minimum weight of sample required to obtain a valid result from the Respirio Flu Test.
Scores from questionnaire to assess ease of use, comfort and convenience of Respirio Flu Test.	Day 1	The ease of use questionnaire will provide the following: • Total number of responses to each question and the percentage of participants selecting each response (most on a 5 point Likert scale).
Of participants positive for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza B by Respirio Flu Test.	Day 1	Establish sensitivity against a gold standard. Report as a percentage of participants with 95% confidence limits.
Percent of participants positive for influenza A by Sofia® Influenza A+B Test and Respirio Flu Test.	Day 1	Establish positive agreement against an imperfect standard. Report as a percentage of participants with 95% confidence limits.
Combine positive and negative agreement of Respirio Flu Test and Sofia® Influenza A+B Test to establish overall agreement. Report as a percentage of participants with 95% confidence limits.	Day 1
Of participants negative for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza B by Respirio Flu Test.	Day 1	Establish specificity against a gold standard. Report as a percentage of participants with 95% confidence limits.
Percent of participants correctly determining eligibility and conditions for use of Respirio Flu Test from scores on a label comprehension questionnaire.	Day 1	The label comprehension questionnaire will provide the following data; * Total number of responses to the question and the percentage of participants selecting each option.; * Number and percentage of participants selecting the correct answer to each question.; * Overall percentage of patients with an acceptable level of comprehension.
Percent of participants negative for influenza B by Sofia® Influenza A+B Test and Respirio Flu Test.	Day 1	Establish negative agreement against an imperfect standard. Report as a percentage of participants with 95% confidence limits.

Trial Locations

Locations (4)

Graceville Medical; 🇦🇺 Brisbane, Queensland, Australia

Taringa 7 Day Medical Practice; 🇦🇺 Brisbane, Queensland, Australia

Inala Primary Care; 🇦🇺 Brisbane, Queensland, Australia

Limestone Medical Centre; 🇦🇺 Ipswich, Queensland, Australia